Escape from therapy-induced accelerated cellular senescence in p53-null lung cancer cells and in human lung cancers - PubMed (original) (raw)

Escape from therapy-induced accelerated cellular senescence in p53-null lung cancer cells and in human lung cancers

Rachel S Roberson et al. Cancer Res. 2005.

Abstract

Accelerated cellular senescence (ACS) has been described for tumor cells treated with chemotherapy and radiation. Following exposure to genotoxins, tumor cells undergo terminal growth arrest and adopt morphologic and marker features suggestive of cellular senescence. ACS is elicited by a variety of chemotherapeutic agents in the p53-null, p16-deficient human non-small cell H1299 carcinoma cells. After 10 to 21 days, infrequent ACS cells (1 in 10(6)) can bypass replicative arrest and reenter cell cycle. These cells express senescence markers and resemble the parental cells in their transcription profile. We show that these escaped H1299 cells overexpress the cyclin-dependent kinase Cdc2/Cdk1. The escape from ACS can be disrupted by Cdc2/Cdk1 kinase inhibitors or by knockdown of Cdc2/Cdk1 with small interfering RNA and can be promoted by expression of exogenous Cdc2/Cdk1. We also present evidence that ACS occurs in vivo in human lung cancer following induction chemotherapy. Viable tumors following chemotherapy also overexpress Cdc2/Cdk1. We propose that ACS is a mechanism of in vivo tumor response and that mechanisms aberrantly up-regulate Cdc2/Cdk1 promotes escape from the senescence pathway may be involved in a subset of tumors and likely accounts for tumor recurrence/progression.

PubMed Disclaimer

Cited by

PKCι depletion initiates mitotic slippage-induced senescence in glioblastoma.
Restall IJ, Parolin DA, Daneshmand M, Hanson JE, Simard MA, Fitzpatrick ME, Kumar R, Lavictoire SJ, Lorimer IA. Restall IJ, et al. Cell Cycle. 2015;14(18):2938-48. doi: 10.1080/15384101.2015.1071744. Cell Cycle. 2015. PMID: 26208522 Free PMC article.
Cellular senescence and cancer chemotherapy resistance.
Gordon RR, Nelson PS. Gordon RR, et al. Drug Resist Updat. 2012 Feb-Apr;15(1-2):123-31. doi: 10.1016/j.drup.2012.01.002. Epub 2012 Feb 23. Drug Resist Updat. 2012. PMID: 22365330 Free PMC article. Review.
A chemogenomic screening identifies CK2 as a target for pro-senescence therapy in PTEN-deficient tumours.
Kalathur M, Toso A, Chen J, Revandkar A, Danzer-Baltzer C, Guccini I, Alajati A, Sarti M, Pinton S, Brambilla L, Di Mitri D, Carbone G, Garcia-Escudero R, Padova A, Magnoni L, Tarditi A, Maccari L, Malusa F, Kalathur RK, A Pinna L, Cozza G, Ruzzene M, Delaleu N, Catapano CV, Frew IJ, Alimonti A. Kalathur M, et al. Nat Commun. 2015 Jun 18;6:7227. doi: 10.1038/ncomms8227. Nat Commun. 2015. PMID: 26085373
Characterization of Senescence of Culture-expanded Human Adipose-derived Mesenchymal Stem Cells.
Legzdina D, Romanauska A, Nikulshin S, Kozlovska T, Berzins U. Legzdina D, et al. Int J Stem Cells. 2016 May 30;9(1):124-36. doi: 10.15283/ijsc.2016.9.1.124. Int J Stem Cells. 2016. PMID: 27426094 Free PMC article.
Identification and characterization of Cardiac Glycosides as senolytic compounds.
Triana-Martínez F, Picallos-Rabina P, Da Silva-Álvarez S, Pietrocola F, Llanos S, Rodilla V, Soprano E, Pedrosa P, Ferreirós A, Barradas M, Hernández-González F, Lalinde M, Prats N, Bernadó C, González P, Gómez M, Ikonomopoulou MP, Fernández-Marcos PJ, García-Caballero T, Del Pino P, Arribas J, Vidal A, González-Barcia M, Serrano M, Loza MI, Domínguez E, Collado M. Triana-Martínez F, et al. Nat Commun. 2019 Oct 21;10(1):4731. doi: 10.1038/s41467-019-12888-x. Nat Commun. 2019. PMID: 31636264 Free PMC article.

Escape from therapy-induced accelerated cellular senescence in p53-null lung cancer cells and in human lung cancers - PubMed (original) (raw)